Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-21T14:41:04.710Z Has data issue: false hasContentIssue false
  • English
  • Français

Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels

Published online by Cambridge University Press:  12 April 2017

Uğur Akcan ,
Sercan Karabulut ,
Cem İsmail Küçükali ,
Sibel Çakır  and
Erdem Tüzün
Uğur Akcan
Affiliation:
Department of Neuroscience, Aziz Sancar Institute of Experimental Medical Research, Istanbul University, Istanbul, Turkey
Sercan Karabulut
Affiliation:
Department of Psychiatry, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Cem İsmail Küçükali
Affiliation:
Department of Neuroscience, Aziz Sancar Institute of Experimental Medical Research, Istanbul University, Istanbul, Turkey
Sibel Çakır
Affiliation:
Department of Psychiatry, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Erdem Tüzün*
Affiliation:
Department of Neuroscience, Aziz Sancar Institute of Experimental Medical Research, Istanbul University, Istanbul, Turkey
*
*Erdem Tüzün, Department of Neuroscience, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul 34390, Turkey. Tel: +90-2124142000; Fax: +90-2124142001; E-mail: drerdem@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Bipolar disorder (BD) patients have recently been shown to exhibit increased proinflammatory cytokine levels indicating the role of inflammation in this disease. As inflammatory responses often include complement level alterations and complement production is influenced by cytokines, we aimed to find out whether complement system is activated in BD in a time-dependent manner and complement factors are involved in BD pathogenesis.

Methods

Serum C4, factor B, sC5b-9 and neuron-specific enolase levels were measured by enzyme-linked immunosorbent assay, whereas peripheral blood mononuclear cell messenger RNA (mRNA) expression levels of C1q, C4, factor B and CD55 were measured by real-time polymerase chain reaction in chronic BD patients (n=22), first episode BD patients (n=24) and healthy controls (n=19).

Results

Serum complement levels were significantly reduced in chronic BD patients as compared with first episode BD patients and healthy controls. Serum levels of complement factors showed significant inverse correlation with disease duration, severity of manic symptoms and serum neuron-specific enolase levels. In chronic BD patients, peripheral blood mononuclear cell mRNA expression levels of C1q, C4 and factor B were significantly elevated, whereas the mRNA expression level of the complement inhibitor CD55 was significantly reduced.

Conclusions

Our results suggest that complement factor levels are reduced in BD presumably due to overconsumption of the complement system and complement production is increased at mRNA level possibly as a compensation measure. Complement factors might potentially be used as indicators of disease severity, neuronal loss and cognitive dysfunction.

Keywords

bipolar disorderC4CD55complementfactor B
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 30 , Issue 2 , April 2018 , pp. 70 - 78
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Belmaker, RH. Bipolar disorder. N Engl J Med 2004;351:476–486.Google Scholar
2. Berk, M, Kapczinski, F, Andreazza, AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804–817.CrossRefGoogle ScholarPubMed
3. Drexhage, RC, Knijff, EM, Padmos, RC et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010;10:59–76.Google Scholar
4. Cunha, AB, Andreazza, AC, Gomes, FA et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008;258:300–304.Google Scholar
5. Ozdemircan, A, Dasdemir, S, Kucukali, CI, Bireller, ES, Ozturk, H, Cakmakoglu, B. COX-2 gene variants in bipolar disorder-I. Psychiatr Danub 2015;27:385–389.Google Scholar
6. Bhattacharya, A, Derecki, NC, Lovenberg, TW, Drevets, WC. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl) 2016;233:1623–1636.CrossRefGoogle ScholarPubMed
7. Dickerson, F, Stallings, C, Origoni, A et al. Pentraxin 3 is reduced in bipolar disorder. Bipolar Disord 2015;17:409–414.Google Scholar
8. Foldager, L, Köhler, O, Steffensen, R et al. Bipolar and panic disorders may be associated with hereditary defects in the innate immune system. J Affect Disord 2014;164:148–154.Google Scholar
9. Soczynska, JK, Kennedy, SH, Goldstein, BI, Lachowski, A, Woldeyohannes, HO, Mcintyre, RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009;30:497–521.CrossRefGoogle ScholarPubMed
10. Rosenblat, JD, Mcintyre, RS. Bipolar disorder and inflammation. Psychiatr Clin North Am 2016;39:125–137.Google Scholar
11. Tsiftsoglou, SA, Sim, RB. Human complement factor I does not require cofactors for cleavage of synthetic substrates. J Immunol 2004;173:367–375.Google Scholar
12. Mevorach, D, Mascarenhas, JO, Gershov, D, Elkon, KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998;188:2313–2320.Google Scholar
13. Pasch, MC, Van Den Bosch, NH, Daha, MR, Bos, JD, Asghar, SS. Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J Invest Dermatol 2000;114:78–82.CrossRefGoogle ScholarPubMed
14. Hamidinia, M, Ghafourian Boroujerdnia, M, Talaiezadeh, A et al. Increased P-35, EBI3 Transcripts and other Treg markers in peripheral blood mononuclear cells of breast cancer patients with different clinical stages. Adv Pharm Bull 2015;5:261–267.Google Scholar
15. Dalle Lucca, JJ, Li, Y, Simovic, MO et al. Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters. J Surg Res 2013;179:153–167.Google Scholar
16. Fischer, B, Schmoll, H, Riederer, P, Bauer, J, Platt, D, Popa-Wagner, A. Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer’s patients. J Mol Med (Berl) 1995;73:465–471.Google Scholar
17. Mayilyan, KR, Weinberger, DR, Sim, RB. The complement system in schizophrenia. Drug News Perspect 2008;21:200–210.Google Scholar
18. Wadee, AA, Kuschke, RH, Wood, LA, Berk, M, Ichim, L, Maes, M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002;17:175–179.CrossRefGoogle ScholarPubMed
19. Santos Sória, LD, Moura Gubert, CD, Ceresér, KM, Gama, CS, Kapczinski, F. Increased serum levels of C3 and C4 in patients with schizophrenia compared to euthymic patients with bipolar disorder and healthy. Rev Bras Psiquiatr 2012;34:119–120.Google Scholar
20. Barbosa, IG, Bauer, ME, Machado-Vieira, R, Teixeira, AL. Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014;2014:360481.Google Scholar
21. Zou, L, Feng, Y, Xu, G, Jian, W, Chao, W. Splenic RNA and microRNA mimics promote complement factor B production and alternative pathway activation via innate immune signaling. J Immunol 2016;196:2788–2798.Google Scholar
22. Nesargikar, PN, Spiller, B, Chavez, R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol 2012;2:103–111.CrossRefGoogle ScholarPubMed
23. Markiewski, MM, Lambris, JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715–727.Google Scholar
24. Manaye, KF, Lei, DL, Tizabi, Y, Dávila-García, MI, Mouton, PR, Kelly, PH. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J Neuropathol Exp Neurol 2005;64:224–229.Google Scholar
25. Stevens, B, Allen, NJ, Vazquez, LE et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007;131:1164–1178.Google Scholar
26. Antonopoulos, CN, Kadoglou, NP. Biomarkers in silent traumatic brain injury. Curr Pharm Des 2016;22:680–687.CrossRefGoogle ScholarPubMed
27. Streitbürger, DP, Arelin, K, Kratzsch, J et al. Validating serum S100B and neuron-specific enolase as biomarkers for the human brain – a combined serum, gene expression and MRI study. PLoS One 2012;7:e43284.Google Scholar
28. Wiener, CD, Jansen, K, Ghisleni, G et al. Reduced serum levels of neuron specific enolase (NSE) in drug-naïve subjects with major depression and bipolar disorder. Neurochem Res 2013;38:1394–1398.Google Scholar
29. Fizazi, K, Cojean, I, Pignon, JP et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998;82:1049–1055.Google Scholar
30. Sasaki, T, Nanko, S, Fukuda, R, Kawate, T, Kunugi, H, Kazamatsuri, H. Changes of immunological functions after acute exacerbation in schizophrenia. Biol Psychiatry 1994;35:173–178.Google Scholar